ArticleKidney medicine2026
Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Chronic kidney disease (CKD) is a growing burden worldwide and in Denmark, with substantial clinical and economic consequences. Although national guidelines recommend sodium/glucose transporter 2 inhibitors (SGLT2i) for patients with CKD, type 2 diabetes (T2D) or heart failure (HF), underdiagnosis limits the use of SGLT2i. This study aims to inform decision makers in health care about the cost-effectiveness of current guidelines for CKD in Denmark focusing on SGLT2i dapagliflozin added to standard of care (SoC) versus SoC alone in patients with CKD. Study Design: Cost-effectiveness analysis based on a Markov model with a lifetime horizon. Setting & Participants: Danish health care payer perspective including a broad population with CKD and subgroups stratified by urinary albumin-creatine ratio (UACR), T2D status, and HF history. Exposures: Dapagliflozin plus SoC versus SoC alone. Outcomes: Quality-adjusted life years (QALYs), life-years, total costs, and incremental cost-effectiveness ratios (ICERs). Analytical Approach: A published Markov model was populated using data from the DAPA-CKD and DECLARE-TIMI 58 trials. Analyses were conducted for the overall population and stratified subgroups. Results were evaluated against an assumed willingness-to-pay (WTP) threshold of €24,158 per QALY. Results: Dapagliflozin treatment resulted in health benefits (QALYs) and life-years versus SoC irrespective of T2D/HF status or UACR levels. Dapagliflozin was cost-effective for the total population with an ICER of €7,499/QALY and dominant for subgroups with high UACR (≥200 mg/g) regardless of T2D/HF status. ICERs were below WTP threshold for all subgroups. However, for patients with CKD and low UACR (<200 mg/g) without T2D/HF, time to cost-effectiveness was long, and estimates were uncertain. Limitations: Results are limited by generalizability, long-term uncertainty, simulated subgroup data, cost uncertainty, and lack of a Danish WTP threshold. Conclusions: This study indicates that dapagliflozin added to SoC is cost-effective across CKD subgroups as recommended in the current Danish guideline recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.